CN106389374A

CN106389374A - Pharmaceutical composition containing LCZ696 and preparation method of pharmaceutical composition

Info

Publication number: CN106389374A
Application number: CN201610630264.4A
Authority: CN
Inventors: 宋科; 周红; 叶冠豪
Original assignee: Shenzhen Salubris Pharmaceuticals Co Ltd
Current assignee: Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date: 2015-08-03
Filing date: 2016-08-03
Publication date: 2017-02-15
Also published as: CN106397249A; WO2017020841A1; CN106397248A

Abstract

The invention provides an LCZ696 pharmaceutical composition containing special LCZ696 crystal powder. On the basis of special powder characteristics of the adopted LCZ696 crystal powder, preparation technological requirements are satisfied and the prepared pharmaceutical composition conforms to clinical medication requirements, so that the geometric amplification of the pharmaceutical composition is achieved.

Description

A kind of pharmaceutical composition containing LCZ696 and preparation method thereof

Technical field

The invention belongs to field of medicaments, particularly to a kind of pharmaceutical composition containing LCZ696 that can be used for heart failure treatment And preparation method thereof.

Background technology

Heart failure (abbreviation heart failure), is because any cardiac structure or dysfunction lead to ventricular filling or penetrate blood ability One group of impaired complex clinical syndrome.Heart failure main clinical manifestation is dyspnea and weak (limited by activity tolerance), And fluid retention (pulmonary venous pleonaemia and periphery edema).Heart failure is the serious and whole end stage of various heart diseases, and sickness rate is high, is Now one of most important cardiovascular disease (《Chinese diagnosing patients with heart failure and treatment guidelines 2014》).

Since two thousand five, popular due to cardiovascular risk factors, the number of the infected of China cardiovascular diseasess is in continue Increased situation.According to statistics, China's cardiovascular patient be about 2.9 hundred million people, wherein heart failure sufferer there are about 4,500,000 people (《In State cardiovascular diseasess report 2013》).Angiotensin-convertion enzyme inhibitor (ACEI) be proved to reduce heart failure patient dead The first kind medicine of rate of dying, is also the most medicine of evidence-based medical accumulation, the choice drug of the treatment heart failure being well recognized as, according to Puli is drawn as to be usually used in one of ACEI of clinical heart failure treatment.

LCZ696(CAS:936623-90-4) be by one kind that Novartis Co., Ltd researches and develops have angiotensin receptor block and Neutral endopeptidase suppresses the cardiotonic agents of dual function, and its structure is first public in patent WO2007056546 (as follows Formula).This compound is the supramolecular complex containing 2.5 water of crystallization (complex) trisodium salt, is led to by Valsartan and AHU377 Cross non-covalent bond combination to form.

Disclosed clinical trial results show, compared with Enalapril treatment group, LCZ696 makes experimenter because of mental and physical efforts Exhaustion admission rate have dropped 21%, and decreases the symptom of heart failure and body limits, and is reducing the dead of heart failure patient Rate of dying and admission rate aspect be better than Enalapril (N Engl J Med, 2014,371 (1):993-1004).As can be seen that LCZ696 is a kind of great market potential cardiotonic agents, and product is in the second half year in 2015 granted listing.

Because LCZ696 is a kind of special medicine, its have special bonding and become salt mode so that its to wet, hot not Stable, and can dissociate in solution system, therefore, even if under conventional production environment, LCZ696 still can be because of suction The reasons such as tide lead to Quality Down.So, to shorten during the production of LCZ696 clinical application, preparation etc. as far as possible its with empty The time of contact of gas, and the use of the technique that keeps from heat (as pulverizing etc.).

Patent WO2007056546 embodiment 1～embodiment 3 discloses the preparation method of LCZ696, according to the method preparation The LCZ696 obtaining, shows in iodine so that its sucking filtration speed in last handling process is extremely slow in superfine powder shape Particularly evident, even during sucking filtration whole using nitrogen protection, products obtained therefrom still exists and leads to product because of the moisture absorption The possibility becoming sticky, thus affecting technology stability, in addition, superfine powder is also unfavorable for that follow-up preparation process preparation of preparation is produced Product.

Patent WO2009061713 discloses a series of preparation of LCZ696, and it is good, surely that this preparation series has dissolving out capability Qualitative high the features such as, but in formulation art, for product that is specific, having multiple specifications simultaneously, from clinical application and The angle that technique simplifies is set out, and fixed prescription and technique need to realize simultaneously etc., and ratio amplifies/reduces, that is, do not change prescription, On the premise of technique, realize that preparation specification equimultiple is amplified/reduced and preparation dissolving out capability still conforms to clinical application requirement, simultaneously Preparation dissolving out capability no crosses great fluctuation process, and patent WO2009061713 accompanying drawing shows its each specification preparation and be not implemented etc. that ratio is put Greatly, prior art is also not disclosed and realizes LCZ696 preparation etc. than the solution amplified/reduce.

In summary, prior art be not provided with being directly synthesized acquisition, be conducive to synthesizing and preparation process LCZ696 crystalline powder, is also not implemented the optimization of LCZ696 preparation prescription and technique, therefore finds a kind of LCZ696 crystal powder End and realize LCZ696 preparation prescription, the optimization of technique is the technical problem that prior art does not solve.

Content of the invention

First of the present invention aims to overcome that the deficiencies in the prior art, provides one kind directly to prepare by synthesis first The LCZ696 crystalline powder obtaining, described crystalline powder has, in building-up process, the features such as be easy to sucking filtration, and can be directly used for In production process, the pulverizing process before preparation can be avoided, be conducive to preparation process to simplify (as material mixing etc.), gained preparation exists Realize preparation properties (as dissolving out capability etc.) optimized simultaneously, the ratio such as realization amplifies/reduces.

The above-mentioned beneficial effect of the present invention is achieved through the following technical solutions：

A kind of crystalline powder of LCZ696 is it is characterised in that 20 μm≤D of described crystalline powder₉₀≤100μm.

Specifically, such as it is not specifically noted, in the present invention, the powder property of all LCZ696 crystalline powders is (as D₉₀、D₅₀ Deng) be and record gained powder body is dried crossing after 80 mesh sieves (about 200 μm of aperture), the purpose sieved is to remove and is being dried on a small quantity During caking LCZ696 product.In building-up process, the powder body of too low particle diameter is unfavorable for that product filters, and is filtering, drying Easily there is the moisture absorption in dry process, and the product of the too high particle diameter then correspondence relatively longer crystallize time, do not meet synthesis technique optimum Requirement, and the product of too high particle diameter there is also the problem that cannot realize in the formulation etc. than amplifying/reducing；When LCZ696 crystallization Powder is in 20 μm≤D₉₀≤ 100 μm, preferably 25 μm≤D₉₀When≤75 μm, it is possible to achieve rapid filtration, it is to avoid product because with air Time of contact is long and the moisture absorption becomes sticky and affects product quality；Meanwhile, also avoid product long time drying in aftertreatment technology, And caking phenomenon in products obtained therefrom after drying；It is furthermore preferred that described 30 μm≤D of LCZ696 crystalline powder₉₀≤60μm.Further , described LCZ696 crystalline powder meets 5 μm≤D simultaneously₅₀≤ 50 μm, preferably 8 μm≤D₅₀≤30μm.

Second object of the present invention is to provide a kind of preparation method of above-mentioned LCZ696 crystalline powder, and the method is permissible Stable preparation has the LCZ696 crystalline powder of aforementioned powder property, and gained crystalline powder need not be pulverized after being used directly for In continuous preparation process, the method is applied to industrial amplification production, and methods described adopts process route as follows.

Methods described comprises following preparation process：

1) at a temperature of less than 30 DEG C, free AHU377 is together molten clear mixed in solvent orange 2 A/solvent B with Valsartan Close solution；

2) it is slowly dropped into sodium hydrate aqueous solution at a temperature of less than 30 DEG C, be warming up to 50～55 DEG C of reaction 20- 30min；

3) it is cooled to 40～45 DEG C, add the LCZ696 crystal seed being equivalent to Valsartan 0.1～5.0wt%, solution turned cloudy, Subsequently it is cooled to 30 DEG C～35 DEG C by the speed of 0.5～1.5 DEG C/10min；

4) reactant liquor is moved to 5～25 DEG C of stirring 1～5h；

5) filter, after vacuum drying, obtain LCZ696 crystalline powder.

If no special instructions, room temperature of the present invention refers to 20 ± 5 DEG C.Reactions steps 1) in free AHU377 husky with figured silk fabrics Smooth mol ratio follows the conventional setting principle to such reaction rate of charge in this area it is preferred that free AHU377 is husky with figured silk fabrics Smooth mol ratio is 1：0.95～1.05, adopted free AHU377 and preferred purity >=99.0% of Valsartan.Described free AHU377 AHU377 salt can be dissociated and obtain, described AHU377 salt (M) can be common slaine or non-metal salt, as sodium Salt, potassium salt, calcium salt, magnesium salt, zinc salt, ammonium salt, triethylamine salt, diethylamine salt etc., preferred calcium salt.One of the present invention is preferably Scheme, described free AHU377 is obtained using following steps：

A) AHU377 salt and isopropyl acetate (IPAC) are placed in reactor, at a temperature of less than 30 DEG C, Deca 2N HCl, stirs to clarify；

B) divide liquid and collect organic faciess, washing, be dried, obtain free AHU377 after precipitation.

For different effective ingredient, the brilliant condition practised of its impact has differences, and for LCZ696, using above method is The LCZ696 crystalline powder with aforementioned powder property can be obtained (as D₉₀And/or D₅₀Deng).The key problem in technology of this preparation process exists In step 1) in the species of solvent and proportioning in mixed solution, one of which is good solvent with respect to LCZ696, another kind of for not Good solvent, and control certain mixed solvent ratio, obtains product using cooling crystallize method, the ratio of good solvent raise and/or Slow cooling crystallize is conducive to obtaining the larger crystalline powder of particle diameter, and poor solvent ratio raises and/or room temperature crystallize is conducive to Obtain the less crystalline powder of particle diameter.Specifically, described solvent orange 2 A is poor solvent, in acetone, oxolane, acetonitrile etc. Any one, described solvent B be good solvent, any one in isopropanol, n-butyl alcohol, isobutanol etc., described solvent orange 2 A The preferably relatively low acetone of toxicity；Maximize to realize yield while ensureing that product cut size meets the requirements, described step In the mixed solution of rapid 1), the volume mass of solvent orange 2 A and Valsartan is than for 6～10:1ml:1g, the purpose of this step be by AHU377 and Valsartan are molten clear, and ensure that certain solvent saturation is beneficial to crystal and separates out it is preferred that in described mixed solution The volume mass of solvent orange 2 A and Valsartan is than for 7～9:1ml:1g；In step 1) in described mixed solution, described solvent orange 2 A and solvent Volume ratio V of B_A:V_B=1-7:1, equally, the solvent of special ratios can ensure that certain solvent saturation, is conducive to crystal to analyse Go out volume ratio V it is preferred that described solvent orange 2 A and solvent B_A:V_B=4-6:1.

In order to make, LCZ696 is as much as possible to be separated out from system, can subsequently add solvent orange 2 A with preparation technology, to reach raising The purpose of yield.Specifically, in step 4) in supplement add mixed solution in 1.0～3.0 times of solvent orange 2 A volume solvent orange 2 A, permissible LCZ696 is separated out further from dicyandiamide solution, and reaches the purpose improving yield.Preferably, step 4) can be excellent further Turn to：Reactant liquor is moved to 5～25 DEG C of stirring 0.5～3h, after adding solvent orange 2 A, continues stirring 0.5～2h.

Described step 5) filter preferably under inert gas shielding, the preferred nitrogen of described noble gases.

Research finds, in the range of said method, product only exists the fluctuation of particle diameter, and impurity content fluctuation is less, Therefore said method can ensure that LCZ696 is uniformly separated out with specific physical status, and product yield, powder property also control Excellent state, this LCZ696 powder body sucking filtration process speed advantage substantially, and embody in large-scale production and become apparent from Speed advantage.It is tacky because of the moisture absorption in preparation process that faster sucking filtration speed can be prevented effectively from product, it is to avoid longer baking The dry time, and it is hardened to avoid product to occur, it is to avoid the conventional disintegrating process before preparation.

Third object of the present invention is to optimize further on the basis of preceding method, by gained LCZ696 crystal powder Outside end controls in the range of particular particle size, also hydrolysis impurity is controlled in very low scope.Specifically, described hydrolysis impurity is The hydrolysis impurity of AHU377, its structure such as following formula：

Hydrolysis impurity too high levels may cause adverse effect, and therefore hydrolysis impurity belongs in process of producing product and needs Want one of impurity of priority control.Further stability experiment finds, hydrolysis impurity content and its rate of rise exist certain Association, specifically, for LCZ696 preparation, when 30 days hydrolysis impurity increments of Acceleration study (40 DEG C ± 2 DEG C, 75% ± 5%RH) Then it is assumed that preparation stability is not good during more than 0.1%.The discovery pleasantly surprised by testing us, when in preparation, hydrolysis impurity controls When below 1.0%, its increment is relatively slow, and in Acceleration study (40 DEG C ± 2 DEG C, 75% ± 5%RH) 30 days, hydrolysis impurity increases Amount is far below 0.1%, and gained preparation stability is higher, meets clinical application requirement.

Specifically, the preparation method of low in hydrolysis impurity content LCZ696 of the present invention pass through control sodium hydroxide amount and Concentration controls the purpose of hydrolysis impurity content to reach.Specifically, the consumption of sodium hydroxide does not affect LCZ696 crystalline powder Powder morphology, but product yield and impurity content can be affected, under aforementioned solvents system and preparation process, when Valsartan with made The mol ratio of sodium hydroxide is 1:2.5-3.0, and when sodium hydrate aqueous solution concentration range is 0.5-1.0g/ml, permissible Hydrolysis impurity amount is controlled within 1.0%.Specifically, on the basis of ensureing aforementioned LCZ696 crystalline powder property further Control hydrolysis impurity content to there is technical difficulty, when sodium hydroxide usage amount is excessive, hydrolysis impurity content can be led to increase；Work as hydrogen Sodium oxide usage amount is crossed that I haven't seen you for ages and leads to Yield of final product to reduce, and also can affect the precipitation of crystal.Therefore, comprehensive yied and impurity contain The influence factor of amount is it is preferred that Valsartan is 1 with the mol ratio of the sodium hydroxide being used:2.70-2.95, it is furthermore preferred that work as Valsartan is 1 with the mol ratio of the sodium hydroxide being used:During 2.80-2.90, reaction yield and impurity content situation can reach To optimization.In addition, the concentration of sodium hydroxide is on having certain impact, relatively low concentration in above-mentioned concentration range is corresponding relatively Relatively low yield.

LCZ696 crystalline powder of the present invention, can be without powder due to the advantage of the aspects such as its powder morphology and quality Broken and be directly used in preparation process.Specifically, for the preparation of conventional product, typically require before preparation according to preparation work , by crude drug pretreatment to required state, pretreatment generally includes pulverizing and mistake for skill, the needs of preparation prescription and product attribute The step of sieve.And for LCZ696 product, due to its to wet, thermally labile so that it needs to avoid pulverizing in preparation process Technique, and the crude drug being not added with pretreatment then easily causes the fluctuation of preparation process, product quality, and specifically, particle diameter is excessively thick Lead to material mixing uniformity poor, tablet weight variation during tabletting, may be caused larger, particle diameter is meticulous to lead to material fluidity poor, easy to stick Punching, and tablet weight variation during tabletting, also can be caused larger and unilateral slightly deep.

Inventor has surprisingly found that, in particle size range of the present invention LCZ696 crystalline powder compared with particle size range outside knot Crystalline flour end is more beneficial for dry granulation process, specifically, described LCZ696 crystalline powder has that pretreatment is simple, uniform particle sizes, Process stabilizing, lot-to-lot variability be little etc. to be had advantage and amplifies/reduce it is often more important that the ratios such as prescription can also be realized, and does not change Prescription and technique, you can realize the amplification of preparation specification/reduce.Prescription realization etc. is conducive to respectively advising in production than amplifying/reducing The conversion of lattice product, is the embodiment of prescription technology content.

More than being based on, the 4th purpose of the present invention be to provide a kind of containing LCZ696 crystalline powder of the present invention LCZ696 pharmaceutical composition.

The key realizing above-mentioned beneficial effect in the particle size range of LCZ696 crystalline powder, specifically, for 50mg, The LCZ696 product of 100mg, 200mg and 400mg specification, its meet clinical application requirement needs realize 15min reach 70% with On dissolution, and realize etc. ratio amplify/reduce, be to realize each specification product using identical prescription, technique all to exist 15min reaches more than 70% dissolution, and dissolving out capability fluctuation is less.Had surprisingly found that by testing us, when control raw material Medicine is in 20 μm≤D₉₀When≤100 μm, the LCZ696 product of 50mg, 100mg, 200mg and 400mg specification all can achieve that 15min reaches To more than 70% dissolution, and dissolving out capability fluctuation is less it is preferred that the particle diameter of crude drug is 25 μm≤D₉₀≤ 75 μm, more excellent Choosing, when the particle diameter of crude drug is 30 μm≤D₉₀When≤60 μm, the LCZ696 product of 50mg, 100mg, 200mg and 400mg specification All can achieve that 15min reaches more than 70% dissolution, dissolving out capability fluctuation simultaneously is minimum.

Described LCZ696 pharmaceutical composition contains filler, disintegrating agent, binding agent, and the species of adjuvant, consumption also contribute to The realization of the above-mentioned beneficial effect of LCZ696 crystalline powder.

Specifically, described filler be selected from Microcrystalline Cellulose, Lactose, starch, Pregelatinized Starch, Mannitol, calcium hydrogen phosphate, One of Sorbitol or two or more mixture, preferably microcrystalline cellulose, Mannitol, calcium hydrogen phosphate, Sorbitol；When When LCZ696 mass parts are 1 part, the consumption of described filler is 0.2～0.8 part, preferably 0.3～0.7 part.

Described disintegrating agent is selected from Crospovidone, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, carboxymethyl cellulose One of calcium or two or more mixture, preferably cross-linking sodium carboxymethyl cellulose, Crospovidone, when LCZ696 mass parts During for 1 part, the consumption of described disintegrating agent is 0.04～0.4 part, preferably 0.05～0.3 part；Described disintegrating agent can select in plus, Additional and interior additional mode, preferably interior additional mode；When using interior additional by the way of, that is, pharmaceutical composition comprises interior phase Grain and additional adjuvant, when described interior phase granule comprises the crystalline powder of LCZ696, filler, disintegrating agent, binding agent, interior plus disintegrate Agent is 0.4～3.8 with the mass ratio of additional disintegrating agent:1.

Described adhesive is selected from low-substituted hydroxypropyl cellulose, Hypromellose, sodium carboxymethyl cellulose, polyvidone, second One of base cellulose or two or more mixture, preferably carboxymethyl cellulose sodium, low-substituted hydroxypropyl cellulose, when When LCZ696 mass parts are 1 part, the consumption of described adhesive is 0.05～0.5 part, preferably 0.1～0.4 part.

Described LCZ696 pharmaceutical composition can comprise fluidizer further, and described fluidizer is selected from silicon dioxide, Talcum One of powder or two or more mixture, when LCZ696 mass parts are 1 part, the consumption of described fluidizer is 0.002～ 0.05 part.

Described LCZ696 pharmaceutical composition can comprise lubricant further, and described lubricant is selected from magnesium stearate, hydrogenation One of vegetable oil, polyethylene glycols, stearic acid, Palmic acid, Brazil wax or two or more mixture, work as LCZ696 When mass parts are 1 part, the consumption of described lubricant is 0.01～0.1 part.

It is common that described LCZ696 pharmaceutical composition includes but is not limited to this area such as tablet, granule, capsule, powder Pharmaceutical preparation.Described LCZ696 pharmaceutical composition can also optionally carry out further Cotton seeds, and described coating can be thin film The common types of coatings in this areas such as clothing, sugar-coat, the material that described coating adopts can be using the common coating material in this area, such as Hypromellose, Icing Sugar, Hydroxypropyl Cellulose etc., can also be using conventional commercially available coating material, such as OPADRY

Using the crystalline powder with specific powder property, and under the auxiliary of above-mentioned prescription, described pharmaceutical composition can To realize etc. than the more optimization amplifying/reduce, that is, when by by supplementary material consumption etc. than incremented/decremented thus obtaining different size Preparation when, the dissolving out capability of gained preparation reaches unanimity, and will not be affected than incremented/decremented by supplementary material etc..

The preferred technical scheme of of the present invention, described LCZ696 preparation adopts LCZ696 crystal powder of the present invention End, its prescription is：

The 5th purpose of the present invention there are provided the preparation method of LCZ696 pharmaceutical composition of the present invention, specifically , when described LCZ696 pharmaceutical composition is tablet, described preparation method comprises following preparation process：

(1) former, adjuvant are crossed 40 mesh sieves, standby；

(2) addition interior in prescription is divided and carry out premixing, suppress the mixture after premixing using dry granulating machine, whole Interior phase granule is obtained after grain；

(3) interior phase granule is mixed with additional adjuvant, after mixing, the mixture of gained is carried out tabletting and obtain LCZ696 label.

Optionally coating material commonly used in the art and coating method can be adopted, gained LCZ696 label is coated Process, the material that described coating adopts can be using the common coating material in this area, and such as Hypromellose, Icing Sugar, hydroxypropyl is fine Dimension element etc., can also be using conventional commercially available coating material, such as OPADRY

To sum up, the present invention, from beneficial to realizing LCZ696 synthesis, preparation process optimization, is existed based on LCZ696 crude drug Unstable reality under wet, hot, by particle diameter series connection synthesis and the big technical field of preparation two of effective ingredient, is realized by synthesis The preparation of specified particle diameter effective ingredient, and preparation process optimization realized by gained specified particle diameter effective ingredient.Understand, with Prior art is compared, and the present invention has following technology character and superiority：

1st, provide a kind of LCZ696 crystalline powder directly preparing by synthesis first, described crystalline powder has spy Fixed powder property, it has in building-up process is easy to sucking filtration, it is to avoid the features such as the moisture absorption, and products obtained therefrom does not almost lump existing As pulverizing process can be avoided in production process, be advantageously implemented preparation properties (as dissolving out capability etc.) optimization；

2nd, provide a kind of preparation method of LCZ696 crystalline powder, the method can stably prepare described in there is specific powder body The LCZ696 crystalline powder of property, gained crystalline powder is used directly in follow-up preparation process, and the method is applied to described The industrialized production of LCZ696 crystalline powder；

3rd, provide a kind of preparation method of low in hydrolysis impurity content LCZ696 crystalline powder, described LCZ696 crystalline powder exists Before on the basis of preparation method, by controlling the consumption of sodium hydroxide, further by the water in gained LCZ696 crystalline powder Solution Control of Impurities is in relatively low scope it is ensured that product quality；

4th, provide a kind of LCZ696 pharmaceutical composition containing LCZ696 crystalline powder of the present invention, due to described The LCZ696 crystalline powder that LCZ696 pharmaceutical composition is adopted has specific powder body feature so that it is meeting preparation process Require and be obtained while meet the pharmaceutical composition of clinical application requirement, it is possible to achieve pharmaceutical composition wait than amplifying.

5th, provide a kind of preparation method of LCZ696 pharmaceutical composition of the present invention, the method can be realized preparation and contain There is the tablet of LCZ696.

Brief description

Fig. 1 embodiment 1 gained LCZ696 crystalline powder sieve before grain size distribution

Fig. 2 embodiment 1 gained LCZ696 crystalline powder crosses grain size distribution after 80 mesh sieves

Fig. 3 embodiment 1 gained LCZ696 crystalline powder crosses outside drawing after 80 mesh sieves

Fig. 4 embodiment 2 gained LCZ696 crystalline powder sieve before grain size distribution

Fig. 5 embodiment 2 gained LCZ696 crystalline powder crosses grain size distribution after 80 mesh sieves

Fig. 6 comparative example 1 gained LCZ696 product sieve before outside drawing

Fig. 7 comparative example 1 gained LCZ696 product crosses grain size distribution after 80 mesh sieves

Fig. 8 embodiment 4 gained LCZ696 crystalline powder crosses grain size distribution after 80 mesh sieves

Fig. 9 embodiment 5 gained LCZ696 crystalline powder crosses grain size distribution after 80 mesh sieves

Specific embodiment

With reference to embodiment and accompanying drawing, the present invention is described in further detail, but the embodiment of invention is not limited to This.

First, study on the synthesis part

By adjusting the technological parameters such as dicyandiamide solution, rate of charge, reaction condition, to dicyandiamide solution and rate of charge to product powder Volume property, the impact situation of hydrolysis impurity content are studied.

Embodiment 1

The preparation of AHU377 free acid：

100g AHU377 calcium salt, 1000ml isopropyl acetate are added in the there-necked flask of 2L, Deca 2mol/L salt under ice bath Sour 240ml；Stirring is molten clear；Divide liquid, collected organic layer, and used 600ml water washing twice；Reduce pressure at 38 DEG C precipitation, obtains AHU377 free acid；

The preparation of LCZ696：

Under room temperature, AHU377 free acid, 100g Valsartan and 880ml acetone, 220ml isopropanol add to 3L there-necked flask, Molten clear；Under room temperature, Deca is the sodium hydrate aqueous solution of 0.9g/ml with respect to Valsartan 2.85 equivalent concentration, is warming up to 50 DEG C instead Answer 20min；It is cooled to 45 DEG C, adds crystal seed about 2.0g, after stirring, solution is muddy, press the speed of 1.0 DEG C/10min afterwards by outer temperature It is down to 35 DEG C, at a temperature of then reactant liquor being moved to 15 DEG C, stir 2h；Subsequently instill acetone 1120ml in system again, at 15 DEG C Stirring 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, at 35 DEG C, vacuum dries 8h, dry and obtain solid 188.0g, HPLC detection purity is 99.91%, and hydrolysis impurity content is 0.02%, and its particle diameter distribution is as shown in Figure 1.

Products obtained therefrom is crossed 80 mesh sieves, obtains 184.2g crystalline powder, its D₉₀For 43.90 μm, D₅₀For 10.14 μm, gained is tied The grain size distribution at crystalline flour end is as shown in Fig. 2 outside drawing is as shown in Figure 3.

Embodiment 2

The preparation of AHU377 free acid：

100g AHU377 calcium salt, 1000ml isopropyl acetate are added in the there-necked flask of 2L, Deca 2mol/L salt under ice bath Sour 230ml；Stirring is molten clear；Divide liquid, collected organic layer, and used 600ml water washing twice；Reduce pressure at 38 DEG C precipitation, obtains AHU377 free acid, reduce pressure after adding the dissolving of 250ml isopropanol precipitation being repeated once again；

The preparation of LCZ696：

Under room temperature, AHU377 free acid, 100g Valsartan and 800ml acetone, 220ml isopropanol add to 3L there-necked flask, Molten clear；Under room temperature, Deca is the sodium hydrate aqueous solution of 0.85g/ml with respect to Valsartan 2.95 equivalent concentration, is warming up to 53 DEG C Reaction 30min；Outer temperature drop to 30 DEG C, is added crystal seed about 1.0g, reactant liquor is moved to 20 by the subsequent speed by 1.0 DEG C/10min 2h is stirred at a temperature of DEG C；Subsequently instill acetone 1200ml again in system, keeping temperature stirs 2h；Through Bu Shi leakage under nitrogen protection Bucket sucking filtration, obtains white solid, and at 35 DEG C, vacuum dries 8h, dries and obtains solid 191.3g, yield 85.6%, and HPLC detection purity is 99.33%, hydrolysis impurity content is 0.58%, and its particle diameter distribution is as shown in Figure 4.

Products obtained therefrom is crossed 80 mesh sieves, obtains 188.0g crystalline powder, its D₉₀For 48.07 μm, D₅₀For 10.26 μm, gained is tied The grain size distribution at crystalline flour end is as shown in Figure 5.

Embodiment 3

Because embodiment 1 and embodiment 2 gained crystalline powder particle diameter form are moderate, can realize quick during the course of the reaction Filter.For embodying its compared with prior art existing advantage in terms of filtration, special by the reaction of embodiment 1 and embodiment 2 Scale amplifies 20 times, and it is compared with patent CN200680001733.0 embodiment 3 (calling " comparative example 1 " in the following text), knot Fruit is as follows：

Project	Filter the time (min)	D90(μm)
			Embodiment 1	About 20min	44.68
Embodiment 2	<20min	47.36
			Comparative example 1	About 55min	16.80

Particularly, comparative example 1 gained crystalline powder due in filter process the moisture absorption and there is more serious caking Phenomenon (outward appearance is as shown in Figure 6), shows as by the percent of pass of 80 mesh sieves only about 25%, the particle diameter distribution of gained crystalline powder As shown in Figure 7.

And under contrasting, embodiment 1, embodiment 2 product then can be realized comparatively fast filtering, embody in more large-scale production Become apparent from.

Embodiment 4

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 80ml third Ketone, 15ml isobutanol add in reaction bulb；Under room temperature, with respect to Valsartan 2.9 equivalent, concentration is the hydrogen-oxygen of 0.85g/ml to Deca Change sodium water solution, be warming up to 50 DEG C of reaction 25min；It is cooled to 45 DEG C, add crystal seed about 0.3g, solutions turbid after stirring, subsequently By 1.5 DEG C/10min speed by outer temperature drop to 30 DEG C, at a temperature of reactant liquor is moved to 15 DEG C stir 3h；Subsequently again in system Instill acetone 120ml, keeping temperature stirs 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, at 40 DEG C, vacuum is dried 8h, dries and obtains solid 19.2g, purity 99.83%, and hydrolysis impurity content is 0.12%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 18.5g crystalline powder, its D₉₀For 31.60 μm, D₅₀For 8.40 μm, gained crystallizes The particle diameter distribution of powder is as shown in Figure 8.

Embodiment 5

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 85ml tetrahydrochysene Stir molten clear in furan, 17ml isopropanol addition reaction bulb；Under room temperature, Deca is 0.85g/ with respect to Valsartan 2.9 equivalent concentration The sodium hydrate aqueous solution of ml, is warming up to 50 DEG C of reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 3h by the subsequent speed by 1.5 DEG C/10min at a temperature of reactant liquor is moved to 20 DEG C；Subsequently again Instill THF 135ml in system, keeping temperature stirs 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 40 DEG C Lower vacuum dries 8h, dries and obtains solid 18.9g, purity 99.83%, and hydrolysis impurity content is 0.12%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 18.1g crystalline powder, its D₉₀For 32.95 μm, D₅₀For 8.71 μm, gained crystallizes The particle diameter distribution of powder is as shown in Figure 9.

Embodiment 6

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 70ml third Stir molten clear in ketone, 12ml n-butyl alcohol addition reaction bulb；Under room temperature, Deca is 0.85g/ml with respect to Valsartan 2.9 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 3h by the subsequent speed by 1.5 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 150ml in system, keeping temperature stirs 1h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 40 DEG C Lower vacuum dries 8h, dries and obtains solid 19.5g, purity 99.78%, and hydrolysis impurity content is 0.13%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 18.7g crystalline powder, its D₉₀For 31.16 μm, D₅₀For 8.28 μm.

Embodiment 7

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 88ml third Stir molten clear in ketone, 40ml isopropanol addition reaction bulb；Under room temperature, Deca is 0.85g/ml with respect to Valsartan 2.9 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 2h by the subsequent speed by 0.5 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 120ml in system, keeping temperature stirs 3h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 40 DEG C Lower vacuum dries 8h, dries and obtains solid 18.5g, purity 99.80%, and hydrolysis impurity content is 0.12%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 17.6g crystalline powder, its D₉₀For 87.23 μm, D₅₀For 46.23 μm.

Embodiment 8

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 90ml second Stir molten clear in nitrile, 25ml isopropanol addition reaction bulb；Under room temperature, Deca is 0.85g/ml with respect to Valsartan 2.9 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 2h by the subsequent speed by 1.0 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetonitrile 130ml in system, keeping temperature stirs 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 40 DEG C Lower vacuum dries 8h, dries and obtains solid 19.0g, purity 99.81%, and hydrolysis impurity content is 0.10%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 18.6g crystalline powder, its D₉₀For 50.75 μm, D₅₀For 11.03 μm.

Study on influencing factors 1

Using the inventory of embodiment 1, rate of charge, the amount adding poor solvent and reaction condition, molten by changing mixing The species of good solvent and poor solvent and/or ratio in agent, to study different solvents system gained crystalline powder powder body situation, knot Fruit such as following table：

Understand, when remaining factor is constant, in mixed solvent, poor solvent ratio is higher, and gained LCZ696 product cut size subtracts Little, the rate of filtration is also gradually successively decreased, rapid decrement at about 20 μm, wherein the 1st group in more than 60min, and identical filtercondition Under, the 2nd group is then about 35min.Inventor also finds that dicyandiamide solution and solvent ratios almost do not have shadow for hydrolysis impurity content Ring.

In addition, for reaching big grain size product, needing to extend the crystallize time, specifically, the 7th group of reaction, except reducing, mixing is molten Outside poor solvent consumption reduces in agent, also need to extend the crystallize time to more than 12h after adding poor solvent, just can reach This big grain size product, therefore for LCZ696 product, the product of the too big particle diameter of preparation is simultaneously uneconomical.

Embodiment 9

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 90ml third Stir molten clear in ketone, 20ml isopropanol addition reaction bulb；Under room temperature, Deca is 0.9g/ml with respect to Valsartan 2.6 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 3h by the subsequent speed by 1.0 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 120ml in system, keeping temperature stirs 1h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 35 DEG C Lower vacuum baking material 12h, dries and obtains solid 16.5g, purity 99.92%, and hydrolysis impurity content is 0.03%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 15.8g crystalline powder, its D₉₀For 45.74 μm, D₅₀For 16.34 μm.

Embodiment 10

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 90ml third Stir molten clear in ketone, 20ml n-butyl alcohol addition reaction bulb；Under room temperature, Deca is 0.9g/ml with respect to Valsartan 2.8 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 3h by the subsequent speed by 1.0 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 120ml in system, keeping temperature stirs 1h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 35 DEG C Lower vacuum baking material 12h, dries and obtains solid 17.8g, purity 99.89%, and hydrolysis impurity content is 0.03%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 17.0g crystalline powder, its D₉₀For 40.86 μm, D₅₀For 11.79 μm.

Embodiment 11

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 90ml third Stir molten clear in ketone, 20ml isobutanol addition reaction bulb；Under room temperature, Deca is 0.9g/ml with respect to Valsartan 2.95 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 2h by the subsequent speed by 1.0 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 120ml in system, keeping temperature stirs 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 35 DEG C Lower vacuum baking material 12h, dries and obtains solid 18.9g, purity 99.38%, and hydrolysis impurity content is 0.53%.

Products obtained therefrom is crossed 80 mesh sieves, obtains 18.1g crystalline powder, its D₉₀For 44.48 μm, D₅₀For 14.54 μm.

Comparative example 2

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 90ml third Stir molten clear in ketone, 20ml isopropanol addition reaction bulb；Under room temperature, Deca is 0.9g/ml with respect to Valsartan 2.4 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 3h by the subsequent speed by 1.0 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 120ml in system, keeping temperature stirs 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 35 DEG C Lower vacuum baking material 12h, dries and obtains solid 12.5g, purity 99.90%, and hydrolysis impurity content is 0.02%.

Products obtained therefrom is crossed 80 mesh sieves, only obtains 11.8g crystalline powder, its D₉₀For 42.35 μm, D₅₀For 13.01 μm.

Comparative example 3

Under the conditions of 25 DEG C, by AHU377 free acid (10g AHU377 calcium salt dissociates and obtains), 10g Valsartan and 90ml third Stir molten clear in ketone, 20ml isopropanol addition reaction bulb；Under room temperature, Deca is 0.9g/ml with respect to Valsartan 3.1 equivalent concentration Sodium hydrate aqueous solution, be warming up to 50 DEG C reaction 25min；It is cooled to 45 DEG C, adds crystal seed about 0.3g, after stirring, solution mixes Turbid, outer temperature drop to 30 DEG C, is stirred 3h by the subsequent speed by 1.0 DEG C/10min at a temperature of reactant liquor is moved to 25 DEG C；Subsequently again Instill acetone 120ml in system, keeping temperature stirs 2h；Through buchner funnel sucking filtration under nitrogen protection, obtain white solid, 35 DEG C Lower vacuum baking material 12h, dries and obtains solid 18.5g, purity 96.75%, and hydrolysis impurity content is 1.87%, and products obtained therefrom is in light Yellow.

Products obtained therefrom is crossed 80 mesh sieves, obtains 17.9g crystalline powder, its D₉₀For 43.66 μm, D₅₀For 12.52 μm.

Study on influencing factors 2

Using reaction conditions such as the inventory of embodiment 1, rate of charge, dicyandiamide solutions, by change sodium hydroxide concentration and Concentration, to study the impact to hydrolyzate amount of sodium hydroxide concentration and concentration, such as following table：

As seen from the above table, only there is impact to yield and impurity content in sodium hydroxide concentration, and for powder morphology impact Less.Specifically, the reduction with sodium hydroxide concentration in the scope of protection of the invention, yield is gradually lowered, and works as hydroxide Sodium consumption be less than 2.5 equivalent when, although its particle diameter and impurity situation meet the requirements, its yield drastically drop to 60% with Down it is impossible to meet the requirement of industrialized production；And work as sodium hydroxide concentration when more than 3.0 equivalents (with respect to Valsartan), its Then more than 1.0%, product, after being subsequently prepared into preparation, does not meet the requirement of preparation stability to hydrolysis impurity content.

In addition, in the scope of protection of present invention, the concentration of sodium hydroxide slightly affects on preparation technology, shows as When naoh concentration reduces, with bringing into so that reaction yield decreases of more water.

Comprehensively as can be seen that in synthesis technique, for the powder property of LCZ696 crystalline powder, it is subject to dicyandiamide solution Impact is larger；In addition, in synthesis technique, when the particle diameter of crystalline powder is less, filtration time needed for it is longer, anti-on a large scale Should in particularly evident, this makes product because after being exposed in the air for a long time and the moisture absorption leads to product moisture content to rise therewith, gained Product occurs more serious hardened, is unfavorable for the carrying out of follow-up preparation process；And the content for yield and hydrolysis impurity, its Affected by sodium hydroxide concentration and concentration；And obtain that there is specific powder property, and the relatively low LCZ696 of hydrolysis impurity Crystalline powder, and realize synthesis technique optimum, need by multiple impact such as comprehensive dicyandiamide solution, sodium hydroxide concentration and concentration Factor.

2nd, preparation research part

The product of the different batches being prepared using study on the synthesis part, by crude drug property, preparation prescription and The isoparametric adjustment of technique, understands the impact situations to the quality of the pharmaceutical preparations for the factor such as crude drug property, hydrolysis impurity content.

Embodiment 12

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using embodiment 1 method gained₉₀=43.90 μm, hydrolysis impurity：0.02%) it is former Material medicine.

Preparation method：

1st, former, adjuvant are crossed 40 mesh sieves, standby；

2nd, phase particulate component interior in prescription is carried out premixing, suppress the mixing after premixing using dry granulating machine Thing, whole

Interior phase granule is obtained after grain；

3rd, interior phase granule is mixed with additional Crospovidone and magnesium stearate, by the mixture of gained after mixing Carry out

Tabletting.

Using OPADRY coating polymer, gained label is coated, obtains coated tablet.In preparation process, phase in gained Mobility of particle is good, and gained tablet is unilateral smooth, and tablet weight variation is little.

Embodiment 13

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using embodiment 1 method gained₉₀=43.07 μm, hydrolysis impurity：0.58%) it is former Material medicine.

Prepare LCZ696 label using with embodiment 12 identical method.Using OPADRY coating polymer to gained Label is coated, and obtains coated tablet.

In preparation process, in gained, phase mobility of particle is good, and tabletting obtained sheet chip face is smooth, and tablet weight variation is little.

Embodiment 14

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using embodiment 4 method gained₉₀=31.60 μm, hydrolysis impurity：0.12%) it is former Material medicine.

In preparation process, in gained, phase mobility of particle is good, and gained tablet is unilateral smooth, and tablet weight variation is little.

Embodiment 15

LCZ696 tablet (100mg)

Using embodiment 4 method gained LCZ696 crystalline powder (D90=31.60 μm, hydrolysis impurity：0.12%) it is former Material medicine.

Embodiment 16

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using embodiment 7 method gained₉₀=87.23 μm, hydrolysis impurity：0.13%) it is former Material medicine.

Embodiment 17

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using embodiment 5 method gained₉₀=32.95 μm of hydrolysis impurities：0.14%) it is raw material Medicine.

In preparation process, mutually lack fluidizer due to interior, the mixed effect of supplementary material has fluidizer with respect in prescription Embodiment is slightly poor so that required incorporation time is relatively longer, but the basic zero difference of phase mobility of particle in gained, tabletting obtained sheet Chip face is smooth, and tablet weight variation is little.

Embodiment 18

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using embodiment 5 method gained₉₀=32.95 μm, hydrolysis impurity：0.14%) it is former Material medicine.

In preparation process, in gained, phase mobility of particle is good, due to not adding lubricant, the few part of tabletting gained label Unilateral slightly burr, but outward appearance totally meets pharmacopeia main points and requires.

Comparative example 4

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using comparative example 1 gained₉₀=16.80 μm, hydrolysis impurity：0.04%) it is former Material medicine, using with embodiment 12 identical prescription.

Preparation method with embodiment 12, but in preparation process, because raw material particle size is too small, in dry granulation process once Through sticking phenomenon occurs, but do not affect subsequent technique, the unilateral color of gained label is slightly uneven, compared with embodiment 12～embodiment 16 obtained sheet chip face colors are slightly deep, but entirety still conforms to require.

Comparative example 5

LCZ696 tablet (100mg)

LCZ696 crystalline powder (D using comparative example 3 gained₉₀=43.66 μm, hydrolysis impurity：1.87%) it is former Material medicine, using with embodiment 12 identical prescription.

In preparation process, in gained, phase mobility of particle is good, and gained tablet is unilateral smooth, and tablet weight variation is little.But, due to In crude drug hydrolysis impurity content higher so that label color is slightly dark, in off-white color.

Embodiment 19

Dissolution detects

Using Chinese Pharmacopoeia (2010 editions) annex XC dissolution determination method the second method paddle method, detect embodiment 12～16 and The Dissolution of Tablet situation of comparative example 4～5 gained LCZ696 dry granulation, the data obtained is as shown in the table：

Project	Particle diameter (μm)	15min	30min	45min
					Embodiment 12	43.90	85.50	97.37	98.87
Embodiment 13	48.07	85.73	98.55	99.55
					Embodiment 14	31.60	86.21	97.13	99.91
Embodiment 15	31.60	85.20	98.26	99.46
					Embodiment 16	87.23	81.62	94.50	98.91
Embodiment 17	32.95	85.54	97.35	99.61
					Embodiment 18	32.95	86.45	98.20	99.43
Comparative example 4	16.80	85.31	95.94	99.64
					Comparative example 5	43.66	85.53	96.50	99.97

As can be seen that embodiment 12-18, comparative example's 4-5 gained tablet all realize in 15min more than 70% molten Go out, and in 45min dissolution close to realizing whole dissolutions, meet LCZ696 product clinical application requirement.

Deng than amplification detection (200mg)

The corresponding supplementary material consumption by embodiment 12～16 and comparative example 4-5 is increased and is twice, and adopt identical Technological parameter is pressed into the tablet of 200mg specification.

Using Chinese Pharmacopoeia (2010 editions) annex XC dissolution determination method the second method paddle method, corresponding detection 200mg specification Dissolution of Tablet situation, the data obtained is as shown in the table：

Project	Particle diameter (μm)	15min	30min	45min
					Embodiment 12	43.09	83.45	96.24	99.17
Embodiment 13	48.07	85.37	97.61	99.72
					Embodiment 14	31.60	85.80	96.72	99.45
Embodiment 15	31.60	84.23	94.43	99.28
					Embodiment 16	87.23	74.92	93.07	99.58
Embodiment 17	32.95	84.77	96.82	99.87
					Embodiment 18	32.95	85.54	97.34	99.50
Comparative example 4	16.80	64.73	87.43	98.12
					Comparative example 5	43.66	83.45	96.35	98.43

As can be seen that after waiting than amplifying the tablet being prepared into 200mg specification, each prescription gained tablet dissolving out capability all has To a certain degree decline, wherein embodiment 12-18 and comparative example 5 prescription, technique gained tablet still can be implemented in 15min The dissolution of effective ingredient more than 70%, and in 45min dissolution close to realizing whole dissolutions, meeting LCZ696 product clinical application will Ask, it is possible to achieve preparation etc. is than amplification.

And for comparative example 4, by its used crude drug particle diameter too small so that it is waiting than obtained sheet after amplifying Agent effective ingredient dissolution in 15min is less than 70%, does not meet LCZ696 product clinical application requirement it is impossible to realize the ratio such as preparation Amplify.

In the Scaling carrying out further is tested, the prescription of embodiment 12-18 and comparative example 5, technique are same Sample can realize the Scaling of prescription, technique, and comparative example 4 is then same molten because of tablet effective ingredient in 15min Go out less than 70%, and preparation Scaling cannot be realized.

Scaling experiment (50mg) and further etc. than (400mg) in amplification test it has been found that embodiment 12- 18 and the prescription of comparative example 5 still can realize Scaling/amplification.

Embodiment 20

Stability experiment

By embodiment gained solid oral forms preparation (100mg) under acceleration environment (40 DEG C ± 2 DEG C, RH75% ± 5%) Place 30 days, the situation of change of detection hydrolysis impurity and outward appearance, acquired results are as follows：

By stability experiment as can be seen that hydrolysis impurity content has considerable influence for the quality of the pharmaceutical preparations, specifically, real Apply hydrolysis impurity content in a 12-18 and comparative example 4 and be less than 1.0%, preparation is presented as hydrolysis impurity in accelerated test Increment is less, and, below 0.10%, when Acceleration study completes, formulation aesthetics are white not yet, and significant change does not occur for 60 days increments.

And for comparative example 5, because its hydrolysis impurity content is higher than 1.0% so that it is during accelerated test Hydrolysis impurity increment is larger, and increment is far above 0.10% within 60 days, and in the trend that accelerates, formulation aesthetics when Acceleration study completes Become faint yellow by off-white color, cosmetic variation is obvious.

Influence factor's experiment 4

Obtain different powder properties and impurity content by adjusting the technological parameters such as dicyandiamide solution, rate of charge, reaction condition Crude drug, prepare solid orally ingestible using with embodiment 12 identical prescription and preparation process, be respectively adopted enforcement The technique study crude drug powder property of example 17 and embodiment 18 and impurity content to preparation etc. than amplifying/reduce, preparation stabilization The impact of property,

Result such as following table：

Tested by above influence factor, crude drug particle diameter and hydrolysis impurity content affect respectively preparation etc. ratio put Greatly/reduce and preparation stability.

It is embodied in, preparation etc. is mainly more related to crude drug particle diameter than amplifying/reducing, when crude drug particle diameter D90 is 20 When～100 μm, preparation prescription, technique can be realized etc., and ratio amplifies/reduces, when crude drug particle diameter D90 is at 30～60 μm, gained Preparation dissolving out capability is optimal, and the ratio such as prescription amplifies/reduce best results.

And the stability of preparation is then mainly related to the content of hydrolysis impurity in crude drug, when hydrolysis impurity content in preparation During less than 1.0%, in its Acceleration study, the hydrolysis impurity increment of 30 days is less than 0.10%, meets the LCZ696 quality of the pharmaceutical preparations and requires.

In summary, crude drug size controlling can be solved prescription etc. when 20～100 μm than asking of amplifying/reduce Topic, and control hydrolysis impurity content in crude drug then to advantageously account for improving the problem of preparation stability below 1.0%.

Embodiment 21

Experiment (Behaviors survey) is investigated in untoward reaction

Laboratory sample：

Test sample：Embodiment 12,13 and comparative example 5 gained solid oral forms preparation (0 day)；Negative controls：Adopt With Vehicle controls product deionized water (laboratory preparation).

Laboratory animal：

ICR mice, SPF level, the Animal Sex for test and quantity, jenny：25, buck：25.

Body weight and the range of age, jenny when buying：9.6～13.5g, 3 week old；Buck：10.0～13.0g, 3 Week old.

Dosage：

Vehicle control group 0mg/kg, compound 1 solid oral forms preparation pulverizing, by active component low dose group 1.0mg/ Kg, middle dose group 10mg/kg, high dose group 110mg/kg gastric infusion, administration time is one week (7 days).

Test procedure：

Pole-jump test operates：With the smooth metal bar of a root surface (diameter is about 0.9cm, and length is about 72cm), vertically Erect.In administration before and administration after different time points pole-jump test operate terminate after carry out aerial righting reflex operation：Lift little Rat-tail bar, mice of dishing out after rotation 4 circle, observe the abnormal attitude (side or the back side land) that mice lands, continuously repeat 5 times, And scored according to Irwin ' s behavior rank scores standard.Before administration and the 2nd, 4,8,24 after last administration Hour respectively observes a pole-climbing and aerial righting reflex.After experiment terminates, using excessive CO₂This test survival used is put to death in anesthesia Animal.Neurological deficit score result is all represented with frequency.Above-mentioned data should carry out statistical analysiss using SAS 9.1.

Standards of grading, Irwin ' s behavior rank scores standard：

0 grade：Normal stand

1 grade：Have in 5 times 1～2 time is in lie on one's side

2 grades：Have in 5 times 3～4 times is in lie on one's side

3 grades：5 times complete to be in lie on one's side

4 grades：Have in 5 times 1～2 time is in carry ground

5 grades：Have in 5 times 3～4 times is in carry ground

6 grades：5 times complete to be in carry ground

7 grades：Carry ground and right slow

8 grades：Can not right

Result and discussion：

Embodiment 12,13 gained solid oral forms preparations, because in preparation, hydrolysis impurity content, below 1.0%, adopts Active component 1.0,10 and the point pole-climbing each observing time of 110mg/kg group animal and aerial righting reflex observed result and solvent pair Compare equal no significant difference (P according to group (0mg/kg)>0.05).

The testing result of comparative example 5 gained solid oral forms preparation 10 and 110mg/kg group is divided between 3 grades -5 grades Cloth, Some Animals observe Novel presentation.

From above-mentioned statistical result, in embodiment 12,13 gained solid oral forms preparations, hydrolysis impurity content is 1.0% Hereinafter, solid oral forms preparation adverse reaction rate is very little；And hydrolyze in comparative example 5 gained solid oral forms preparation Impurity content is higher than 1.0%, so that adverse reaction rate substantially increases.But, cause the specifically former of mice untoward reaction Because unknown thus it is speculated that may because excessive hydrolysis impurity content impurity cause solid oral forms preparation produce other specificity impurity or Caused due to the collaborative restrictive function between medicine-impurity it is known that, control crude drug and impurity content for reducing adverse drug Reaction is significant.

Above-described embodiment is the present invention preferably embodiment, but embodiments of the present invention are not subject to above-described embodiment Limit, other any spirit without departing from the present invention and the change made under principle, modification, replacement, combine, simplify, All should be equivalent substitute mode, be included within protection scope of the present invention.

Claims

1. a kind of pharmaceutical composition containing LCZ696, the crystalline powder containing LCZ696, filler, disintegrating agent, binding agent, its It is characterised by the 20 μm≤D of crystalline powder of the LCZ696 that described pharmaceutical composition adopts₉₀≤100μm.

2. the pharmaceutical composition of LCZ696 according to claim 1 is it is characterised in that crystalline powder 25 μ of described LCZ696 m≤D₉₀≤ 75 μm, preferably 30 μm≤D₉₀≤60μm.

3. the pharmaceutical composition of LCZ696 according to claim 1 or 2 any one is it is characterised in that described LCZ696 5 μm≤D of crystalline powder₅₀≤ 50 μm, preferably 8 μm≤D₅₀≤30μm.

4. the pharmaceutical composition of the LCZ696 according to claim 1-3 any one is it is characterised in that described LCZ696 Crystalline powder hydrolysis impurity content is less than 1.0%.

5. the pharmaceutical composition of the LCZ696 according to claim 1-4 any one is it is characterised in that described filler selects From one of Microcrystalline Cellulose, Lactose, starch, Pregelatinized Starch, Mannitol, calcium hydrogen phosphate, Sorbitol or two or more Mixture；When LCZ696 mass parts are 1 part, the consumption of described filler is 0.2～0.8 part.

6. the pharmaceutical composition of the LCZ696 according to claim 1-5 any one is it is characterised in that described disintegrating agent selects One of crospovidone, carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, carboxymethylcellulose calcium or two or more Mixture, when LCZ696 mass parts are 1 part, the consumption of described disintegrating agent is 0.04～0.4 part, and described disintegrating agent can adopt Interior plus, additional and interior additional mode.

7. the pharmaceutical composition of LCZ696 according to claim 6 is it is characterised in that the pharmaceutical composition of described LCZ696 Comprise interior phase granule and additional adjuvant, described interior phase granule comprises the crystalline powder of LCZ696, filler, disintegrating agent, binding agent, Described disintegrating agent using interior additional by the way of, described additional accessory package contain disintegrating agent, the interior matter with disintegrating agent and additional disintegrating agent Amount ratio is 0.4～3.8:1.

8. the pharmaceutical composition of the LCZ696 according to claim 1-7 any one is it is characterised in that described adhesive is selected From one of low-substituted hydroxypropyl cellulose, Hypromellose, sodium carboxymethyl cellulose, polyvidone, ethyl cellulose or two Plant above mixture, when LCZ696 mass parts are 1 part, the consumption of described adhesive is 0.05～0.5 part.

9. the pharmaceutical composition of the LCZ696 according to claim 1-8 any one is it is characterised in that described LCZ696 Pharmaceutical composition in the consumption of filler be 0.3～0.7 part, the consumption of disintegrating agent is 0.05～0.3 part；The consumption of binding agent For 0.1～0.4 part.

10. the pharmaceutical composition of the LCZ696 according to claim 1-9 any one is it is characterised in that described LCZ696 Pharmaceutical composition comprise fluidizer and/or lubricant further, described fluidizer be selected from one of silicon dioxide, Pulvis Talci Or two or more mixture, when LCZ696 mass parts are 1 part, the consumption of described fluidizer is 0.002～0.05 part；Described Lubricant is selected from one of magnesium stearate, hydrogenated vegetable oil, polyethylene glycols, stearic acid, Palmic acid, Brazil wax or two Plant above mixture, when LCZ696 mass parts are 1 part, the consumption of described lubricant is 0.01～0.1 part.

The pharmaceutical composition of 11. LCZ696 according to claim 1 is it is characterised in that the pharmaceutical composition of described LCZ696 Prescription be following any one：

Prescription 1：

Prescription 2：

Prescription 3：

.

The preparation method of the pharmaceutical composition of LCZ696 described in a kind of 12. claim 1-11 any one it is characterised in that Described preparation method comprises following preparation process：

(1) former, adjuvant are crossed 40 mesh sieves, standby；

(2) addition interior in prescription is divided and carries out premixing, using dry granulating machine suppress premixing after mixture, granulate it After obtain interior phase granule；

(3) interior phase granule is mixed with additional adjuvant, after mixing, the mixture of gained is carried out tabletting and obtain LCZ696 Label,

Further across Cotton seeds, described coating adopts Hypromellose, Icing Sugar, Hydroxypropyl Cellulose or Europe bar to described tablet Any one in generation.